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Summary 
Natural killer (NK) cells kill normal and transformed hematopoietic cells that lack expression 
of major histocompatibility complex (MHC) class I antigens. Lysis of HLA-negative Epstein 
Barr virus-transformed B lymphoblastoid call lines (B-LCL) by human NK cell clones can be 
inhibited by transfection of the target cells with certain HLA-A, -I3, or -C alleles. NK cell clones 
established from an individual demonstrate donal heterogeneity in HLA recognition and a single 
NK clone can recognize multiple alleles. We describe a potential human NK cell receptor (NKB1) 
for certain HLA-B alleles (e.g., HLA-B*5101  and-B*5801) identified by the mAb Dxg. NKB1 
is a 70-kD glycoprotein that is expressed on a subset of NK cells and NK cell clones. DX9 monoclonal 
antibody (mAb) specifically inhibits the interaction between NK cell clones and B-LCL targets 
transfected  with certain HLA-B alleles, but does not affect recognition of HLA-A or HLA-C 
antigens. An individual NK cell clone can independently recognize B-LCL targets transfected 
with HLA-B or HLA-C antigens; however, DX9 mAb only affects interaction with transfectants 
expressing certain HLA-B alleles. These findings demonstrate the existence of NK cell receptors 
involved in the recognition of HLA-B and imply the presence of multiple receptors for MHC 
on an individual NK clone. 
N 
'K cells are lymphocytes distinct from T and B cells that 
mediate cell-mediated cytotoxicity and secrete cytokines 
after immune stimulation (1). The specific receptors involved 
in  NK  cell  recognition and activation remain undefined; 
nonetheless, it is becoming increasingly clear that both trig- 
gering and inhibitory molecules dictate their lytic specificity 
NK cell effector function presumably involves a positive signal 
that initiates cytotoxicity and cytokine production. In the 
case of antibody-dependent cellular cytotoxicity, the positive 
signal is generated by the interaction between the Ig-coated 
target and CD16 (Fc',/RIII)  on the NK cell (2). The mem- 
brane receptors responsible for initiating lysis of transformed 
or virus-infected cells in the absence of specific Ig have not 
been identified. 
NK cell-mediated cytotoxicity is also regulated by inhibi- 
tory signals. K~"re et al. (3, 4) initially observed that certain 
murine tumor variants lacking H-2 antigens were more sus- 
ceptible to NK lysis than the parental tumor cells expressing 
high levels of H-2. Similarly, when MHC class I molecules 
were transfected into human HLA class I-deficient B lym- 
phoblastoid cell lines (B-LCL), 1 the transfectants were less 
1 Abbreviation  used in  this paper:  B-LCL, B lymphoblastoid  cell lines. 
susceptible to NK cell lysis than the parental lines (5, 6). Anal- 
ysis of an extensive panel of NK cell clones revealed that human 
NK cells have the ability to recognize multiple HLA-A, -B, 
and -C alleles (7). Two models that could account for this 
phenomenon have been proposed: (a) target interference and 
(b) effector inhibition (3, 4). The target interference model 
postulates that target cell MHC class I molecules mask an- 
tigens that stimulate NK lysis; the effector inhibition model 
proposes that target cell MHC class I molecules interact with 
specific receptors on NK cells, thereby transmitting a nega- 
tive signal that prevents the initiation of cytolysis. Recent 
findings support the latter model (8). 
Karlhofer et al. (8) have identified a class I MHC receptor, 
Ly-49, that is expressed on a subset ofmurine NK cells. The 
interaction between Ly-49 on the NK cell and H-2D a mol- 
ecules on target cells prevents NK cell-mediated cytotoxicity. 
Ly-49 is a type II membrane glycoprotein of the C-type lectin 
superfamily. Ly-49 and a family of at least five related genes 
are on mouse chromosome 6 (9-11). One member of the Ly- 
49 family, SWSE6, (12) appears to be involved in mediating 
the rejection of allogeneic bone marrow cells (13). SW5E6 
and Ly-49 are expressed as disulfide-linked  homodimers; as 
yet, there is no evidence for heterodimers between members 
of the Ly-49 family. Human NK cell receptors for HLA have 
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and Ciccone et al. (15) describe two antigens expressed on 
NK  subsets  that  appear to correlate  with recognition of 
HLA-C. Our studies, however, have demonstrated that NK 
clones  recognize not only HLA-C, but also HLA-A and 
HLA-B (7), suggesting the existence of additional receptors. 
In the present study, we describe an NK cell receptor involved 
in the recognition of HLA-B. 
Materials  and Methods 
NK Clones.  Peripheral  blood from healthy individuals  was pur- 
chased from the Stanford  Blood Bank (Stanford,  CA). NK cell clones 
(CD3-, CD56 +) were established  using the culture conditions de- 
scribed by Yssel et al. (16). 
raAbs andFlow  Cytometry.  mAbs  were provided generously by 
Becton Dickinson Immunocytometry Systems (Mountain View, 
CA).  Cy-chrome  TM  conjugated anti-CD3  was purchased from 
PharMingen (San Diego, CA). The DX9 (IgG1) hybridoma was 
generated  by immunizing BALB/c  mice with the human NK clone 
VL186-1 (CD3-, CD16 +, CD56 +) and fusing their splenocytes 
with the Sp2/0 myeloma  cell line. Fab and F(ab')2 fragments were 
prepared by digesting DX9 IgG with immobilized papain (5 mg 
IgG in 5 ml of 20 mM NaHzPO~, 20 mM cysteine-HC1  buffer, 
pH 7.0, with 1 ml immobilized papain for 7 h at 37~  or im- 
mobilized pepsin (10 mg IgG in 10 ml of 0.2 M sodium citrate, 
0.15 M NaCI buffer, pH 3.5, with 2.5 ml immobilized pepsin for 
2 h at 37  ~  (Pierce, Rockford, IL), respectively, and afterwards 
removing residual intact mAb by protein A affinity chromatog- 
raphy. Purity of the F(ab')2 and Fab fragments was determined by 
SDS-PAGE. Methods  of immunofluorescent staining and flow 
cytometry have been described previously (17). 
Biochemistry.  Cells  were labded  with nsI using lactoperoxi- 
dase/glucose oxidase or  with  [32p]orthophosphate (Amersham 
Corp., Arlington Heights, IL) (18). Cells were lysed  in Tris-buffered 
saline (50 mM Tris, 15 mM NaCI, pH 8.0) containing 1% NP-40 
and protease inhibitors (1 mM PMSF and 20 Kallikrein inhibitor 
U/m1 aprotinin) and phosphatase inhibitors (1 mM EGTA, 10 mM 
NaF,  1  mM  Na4PzO7, 0.1  mM  ~-glycerophosphate, 1  mM 
Na3VO4) or 20 mM triethanolamine/150 mM NaCI buffer (pH 
7.8) containing 1% digitonin (CalBiochem-Novabiochem  Corp., 
La Jolla, CA) and 0.12% Triton X-100 (Sigma Chemical Co., St. 
Louis, MO) with protease inhibitors. NKB1 antigen was immu- 
noprecipitated using the method described previously  (18). NKB1 
glycoprotein  was treated with neuraminidase  (Sigma  Chemical  Co.), 
O-glycanase (Genzyme, Boston,  /VIA), and  N-glycosidase F 
(Boehringer Mannheim Corp., Indianapolis, IN) using the condi- 
tions recommended by the manufacturers. Samphs were analyzed 
by SDS-PAGE. 
Cytotoxicity Assays.  NK cell-mediated cytotoxicity was mea- 
sured using a 4-h SlCr radioisotope release assay (2). Assays were 
performed using an effector/target ratio of 6:1 in the presence and 
absence of DX9 mAb (5/~g/ml). C1R B-LCL (19, 20) (HLA-A-, 
-B'3503 t~  -Cw*0401  +)  and  C1R  transfectants  expressing 
HLA-A'0201, -A*0301, -A'6801,  -B'3701,  and  -B'5801  were 
provided generously  by Dr. Peter Cresswell (Yale University, New 
Haven, CT) and Dr. Jeffrey Dawson (Duke University, Durham, 
NC).  721.221 (HLA-A-,  -B-,  -C-)  and  721.221.B'5101 and 
721.221.Cw*0301 transfectants were provided generously by Dr. 
Robert  DeMurs (University of Wisconsin, Madison, WI) (21). 
721.221 transfectants expressing HLA-A*0201, -A*0211, -?,'3601, 
-B* 3505,  -B'4801,  -B* 5401,  -B* 5501,  -B* 5801,  -Cw*  0102, 
-Cw*0304, -Cw*0401, -Cw*0801, and -Cw'1503 were generated 
as described previously (7). 
Results and Discussion 
Generation and Characterization of DX9 mAt~  Whereas 
many NK cell clones and polyclonal NK populations kill the 
MHC class I-deficient B-LCL C1R and 721.221, transfec- 
tion of these cell lines with certain alleles of HLA-A, -B, 
or -C results in protection from NK cell lysis (5, 6, 7). In 
particular, the products of certain HLA-B alleles (e.g., HLA- 
B'5101, -B'5801) frequently protected against lysis by NK 
clones (7). To identify NK call receptors for HLA, mAbs 
were generated against  an NK done (VL186-1) that was 
strongly inhibited by the expression of HLA-B*5801 on the 
surface of the C1R B-LCL target (7). mAbs were therefore 
sdected for their capacity to permit lysis of the HLA-B*5801 
C1R transfectant and in this manner DX9 mAb was isolated. 
Whereas NK done VL186-1 failed to kill HLA-B*5801-trans- 
fected C1R (0% cytotoxicity), in the presence of mAb DX9 
64% lysis of HLA-B*5801-transfected CIR was observed. 
The DX9 mAb reacted with a molecule on the surface of 
NK done VL186-1, but failed to stain the HLA-B*5801 trans- 
fected C1R, indicating that the effect was due to interaction 
with the NK effector cell and not the target. 
The antigen recognized by DX9 mAb, designated NKB1, 
was  found to be expressed  on the surface of a  subset  of 
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Figure  1.  Expression  of  NKB1 on adult  peripheral  blood NK cells and 
NK cell  clones. (.4) Peripheral  blood  mononuclear  cells  were stained  with 
FITC-conjugated anti-CD56 and PE-conjugated  DX9 mAb or fluoro- 
chrome-conjugated  control  Ig. Samples  were analyzed  by flow  cytometry. 
Lymphocytes  were  identified  by their  characteristic  forward  and side  angle 
light scatter properties. Data are displayed  as contour  plots (4 decade  log 
scales). (B) NKB1  § and NKB1- NK cell clones were established  by single 
cell cloning  using flow  cytometry.  Representative  NKB1- and NKB1  § 
NK clones  were stained  with PE-conjugated  DX9 mAb or PE-conjugated 
control Ig (clg). Histograms  of  DX9 mAb-stained  cells are superimposed 
over histograms of Ig control-stained  cells (nearest the ordinate). 
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(Fig. 1), but was not detected on the surface of granulocytes, 
monocytes, thymocytes,  or B lymphocytes (not shown). Anal- 
ysis of peripheral  blood from 18 normal adult donors indi- 
cated that NKB1 is present from <0.1 to 61% (mean  =  14%) 
of CD3-,  CD56 + NK cells.  The significance of this con- 
siderable heterogeneity is unknown. NKB1 was observed in- 
frequently  on adult peripheral blood CD3 § lymphocytes, al- 
though a minor subset of NKB1 + T cells (<0.1-3%) could 
be detected in certain  individuals  (not shown).  A  panel of 
NKB1 -  and NKB1 + NK clones (all of these were CD3-, 
CD56 + cells) were established  by single cell doning using 
flow cytometry for further analysis.  In all cases,  the NKB1 
phenotype of the clones remained stable (representative clones 
are shown in Fig. 1). We have never observed acquisition of 
NKB1 by NK clones initially isolated as being NKB1-  or 
the loss of NKB1  from NKB1 + NK clones. 
HIM Specificity of  NKB1.  NK clones were established from 
two  donors  on  the  basis  of  NKB1  expression  (CD3-, 
CD56 +, NKB1 + and CD3-,  CD56 +, NKB1 -). Of the 29 
NKB1 + NK clones examined, all lysed HLA-deficient EBV 
transformed B-LCL C1R and demonstrated diminished lytic 
activity against  HLA-B*5801  C1R transfectants.  Cytolysis 
by NKB1 + NK clones against the HLA-B*5801  transfectant 
was augmented  in the presence of DX9  mAb  (Fig.  2  and 
Table  1).  By  contrast,  killing  of the  untransfected  HLA- 
deficient EBV transformed B-LCL cell lines 721.221  and C1R 
by NKB1 + NK clones was neither augmented nor inhibited 
by DX9 mAb (Fig. 2). As shown in Fig. 3, F(ab')2 and Fab 
fragments of the DX9 mAb, like the intact antibody,  were 
able to permit lysis of the HLA-B*5801-transfected 721.221 
target  cell. 
Examination of a panel of transfectants expressing different 
class I HLA genes indicated that DX9 mAb permitted cyto- 
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Figure  2.  The effect of DX9  mAb  on the ability of NK clones  to lyse HLA-deficient  or HLA-transfected  B-LCL  target  cells.  Two representative 
NKB1 +  NK clones A4 and 47 were assayed for cytotoxicity against  721.221, C1R, or the indicated HLA  transfectants  in the presence (st@ed Mrs) 
or absence (solid bars)  of DX9  mAb  (5/*g/ml). The E/T ratio was 6:1. 
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Figure  3.  Effect of F(ab')2 and Fab fragments  of DX9 mAb on the 
ability of NKB1 + NK clone A13 to lyse HLA-B* 5801-transfected 721.221 
target calls.  NKB1 + NK done A13 was assayed  for cytotoxicity against 
HLA-B* 5801-transfected 721.221 target cells in the presence of intact DX9 
mAb (diamonds),  DX9 F(ab')2 fragments (circles),  and DX9 Fab fragments 
(triangles) as indicated.  Anti-CD56  (Leu  19) mAb (squares) was used as 
the control Ig. Leu 19 is a murine IgG1 mAb that binds to all NK cells, 
but does not affect NK cell function. All mAb were used at 5/~g/ml and 
were added to the NK cells immediately before addition of the target calls. 
toxicity  against certain  HLA-B  alleles,  in addition  to HLA- 
B'5801,  but  did  not  affect  cytotoxicity  against  any  of the 
HLA-C  transfectants examined.  Representative  data obtained 
from  experiments  with  two  NKB1  +  dones  are  shown  in 
Fig,  2  and  the  results  obtained  from  several  NKB1-  and 
NKB1  +  NK  clones  are  summarized  in  Table  1.  Whereas 
NKB1  +  NK  clones  recognized  and  therefore  failed  to  lyse 
transfectants  expressing  certain  HLA-C  alleles,  including 
-Cw*0102,  Cw*0301,  -Cw*0304,  -Cw*0401,  -Cw*0801,  and 
-Cw'1503,  the presence  of DX9  mAb  had no  effect  on the 
target  protection  conferred  by these  molecules.  This  obser- 
vation demonstrates that binding DX9  mAb  to the NK  clones 
need  not  interfere  with  the  recognition  of all  HLA  mole- 
cules,  but  only  that  of  specific  alleles. 
Individual  NK  clones  have  the  ability  to  recognize  mul- 
tiple alleles of HLA-B  (7). Therefore,  we examined  the effect 
of DX9  mAb  on  NK  cell-mediated  lysis  of B-LCL  trans- 
The DX9 mAb and its F(ab')2 and Fab fragments did not affect NK cell- 
mediated lysis of the HLA-negative 721.221 EBV-LCL target cells (Fig, 
2  and not shown). 
Table  1.  Lysis of HLA  Transfected Target  Cells in the Presence and Absence of DX9  mAb 
CltL  transfectants  721.221  transfectants 
B'3701  B'5801  B'5101  Cw*0301  Cw*0304  Cw*0401 
NK  No  No  No  No  No  No 
clone  mAb  DX9  mAb  DX9  mAb  DX9  mAb  DX9  mAb  DX9  mAb  DX9 
DX9 §  NK  clones 
A4  +  *  +  -+  +  -  +  ...... 
A6  +  +  -  +  -  +  +  +  nd  nd  ndS  nd 
A7  +  +  -  +  -  +  ...... 
A9  -  -  -  +  -  +  +  +  +  +  -  - 
A21  +  +  -  +  -  +  +  +  +  +  -  - 
A23  +  +  -  +  -  +  ....  +  + 
A26  +  +  -  +  -  +  ...... 
A36  -  -  -  +  -  +  -  -  nd  nd  nd  nd 
DX9-  NK  clones 
B1  +  +  -  -  +  +  ...... 
B2  ....  +  +  +  +  +  +  -  - 
B5  +  +  .......... 
B6  +  +  -  -  +  +  +  +  nd  nd  nd  nd 
B12  +  +  -  -  +  +  +  +  +  +  -  - 
B19  +  +  -  -  +  +  +  +  nd  nd  nd  nd 
*  +  Indicates that the percent specific lysis of the HLA-transfected target cell was comparable with  that of the parental cell line or  substantially 
increased in the presence ofDX9 mAb. In all cases the lysis of the parental cell lines was 30% or greater. The data are a composite of several experiments. 
+ -  Indicates that the percent specific lysis of the HLA-transfected target cell was 50% or less than that of the parental cell line, i.e.,  the NK clone 
recognizes that particular  HLA  allele. 
s nd,  not  determined. 
540  NK  Receptor  NKB1 fectants  expressing  B*0702,  -B'2705,  -B'3505,  -B'3701, 
-B'4801,  -B'5101, -B'5401,  or -B'5501.  We observed that 
DX9 mAb reversed the protection conferred by HLA-B*5101 
consistently, in addition to HLA-B*5801 (Fig.  2 and Table 
1). The DX9 mAb also affected recognition of HLA-B*2705. 
However, the protection conferred by -B'2705 was less than 
with -B'5101 or -B'5801 (Fig. 2). Consistent with previous 
observations (7), NK clones recognizing -B*0702, -B'3505, 
-B'3701, -B'4801, -B'5401, or -B'5501 and the HLA-A al- 
leles  (-A*0201,  -A*0211,  -A*0301,  -A'3601,  -A'6801)  were 
less frequent than NK clones recognizing -B'5801; however, 
preliminary  studies indicate that DX9 mAb has little effect 
upon the lysis of the latter transfectants  (not shown).  Fur- 
ther analysis of NK clones that recognize these less frequently 
protective HLA-A and HLA-B alleles is required to exclude 
reactivity with  these molecules. 
Certain NKB1-  NK cell clones recognized HLA-B* 5801 
and -B'5101, although as expected DX9 mAb failed to affect 
lysis of these transfectants.  Therefore, whereas the results are 
compatible with the possibility that NKB1 is a receptor for 
HLA-B*5801 and -B'5101, they also suggest that additional 
receptors with  this  specificity are also present  on NKB1- 
NK clones.  NKB1 -  NK clones may express  a variant of the 
NKB1 molecule not recognized by the DX9 mAb or a dis- 
tinct receptor that also recognizes HLA-B*5801 and -B'5101. 
There was no apparent  bias in  the recognition  of HLA-A 
or HLA-C alleles by clones derived from either the NKB1- 
or NKB1 + NK subsets,  suggesting the existence  of indepen- 
dent  receptors  for HLA-A and HLA-C. 
Structure of NKB1  Antigen.  The  DX9  mAb  immuno- 
precipitates a 70-kD glycoprotein from 12SI-labeled NKB1 + 
NK cell clones that on SDS-PAGE gels migrates as a single 
species under both reducing and nonreducing conditions (Fig. 
4).  Identical results were obtained using 1% NP-40 or 1% 
digitonin detergent for cell disruption. Treatment with neur- 
aminidase  slightly decreased the mobility of NKB1, indicating 
that the protein is sialated.  Digestion of the NKB1 protein 
with Noglycanase reduced the apparent molecule weight to 
"~50 kD, demonstrating  the presence of complex N-linked 
olignsaccharides.  In contrast,  endo-H and O-glycanase had 
no effect upon the mobility of the NKB1 protein.  Immuno- 
precipitation from NK cell clones metabolically labeled with 
[32p]orthophosphate indicated that NKB1 is phosphorylated. 
Stimulation with PMA neither increased nor decreased phos- 
phorylation  of NKB1. 
Conclusions.  Analysis of the specificity of NK clones against 
a panel of target  cells  transfected with class I MHC mole- 
cules argues  strongly  that  distinct  receptors for individual 
HLA alleles or groups of HLA alleles are expressed by human 
NK  cells.  Our  results  support  the  possibility that  NKB1 
represents one such receptor that is specific for certain HLA-B 
alleles, although formal proof requires evidence for the direct 
interaction  of NKB1 and HLA-B molecules. Several obser- 
vations  suggest  that  NK cell recognition  of HLA is com- 
plex. An individual NK clone can recognize HLA-A, -B, and 
-C  molecules.  Whereas  NKB1 +  NK  clones  all  recognize 
HLA-B*5801, these clones demonstrate heterogeneous rec- 
Figure  4.  Structure  ofNKB1. (A) NKBI* NK clones  were lz~I-labeled 
and lysed  in 1% NP-40. Lysates  were immunoprecipitated with control 
Ig or DX9 mAb and samples analyzed  by SDS-PAGE  in the presence or 
absence of 2-mercaptoethanol. (B) lZSl NKB1 antigen was treated with 
neuraminidase, O-glycanase, endo H, or N-glycanase, as indicated, and 
analyzed by SDS-PAGE  in the presence  of 2-mercaptoethanol. (C) NKB1  § 
NK clones were metabolically  labeled  with [32P]orthophosphate  and were 
then stimulated or not with 1 ng/ml PMA for 5 rain. Cells were lysed 
in 1% NP-40, lysates were immunoprecipitated with control Ig, anti- 
HLA-A, -B, -C mAbs (positive  control) or DX9 mAb and samples ana- 
lyzed by SDS-PAGE in the presence of 2-mercaptoethanol. 
ognition of different HLA-C molecules, implying the exis- 
tence of multiple  NK receptors.  Some NKB1-  NK clones 
were also functionally inhibited by HLA-B*5801, indicating 
the  presence  of  another  HLA-B*5801  receptor  on  the 
NKB1-  subset.  Moreover,  NKB1  appears  to  recognize 
HLA-B*5801,  -B'5101,  and possibly -B'2705. 
It should be noted that NKB1 + NK clones shown in Fig. 
2 were derived from an HLA-B*5801 + donor.  Thus,  both 
the NKB1 receptor and its putative ligand HLA-B*  5801 can 
be expressed by the same NK done. Moreover, NKB1 + NK 
clones from  an  HLA-B*5801 + donor  efficiently lysed the 
HLA-deficient B-LCL CIR, whereas no lysis of C1R.B*5801 
was observed. These results indicate that if a "negative signal" 
is induced it is directional and target specific (i.e., the poten- 
tial interaction  of NKB1 with  HLA-B on either  the same 
or an adjacent NK clone does not prevent the lysis of a sus- 
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the putative inhibitory signal sent through the NKB1 receptor 
does not irreversibly inactivate the NK cell.  Recent studies 
using NK cell lines reactive with HLA-C also support the 
concept that bystander cells expressing inhibitory HLA al- 
leles are unable to affect the interaction between an NK cell 
and a susceptible target  (22). 
Further heterogeneity is introduced by the expression of 
NKB1 on only a subset of NK cells and the variable size of 
this subset in different individuals. A similar situation exists 
with expression of Ly-49 and 5E6, which are expressed only 
on a subset of NK cells in certain mouse strains (9, 13). Simi- 
larly, the EB6 and GL183 antigens implicated in recognition 
of HLA-C are expressed only on partially overlapping subsets 
of human  NK cells  (23). 
Previous studies by Colonna et al. (14) have demonstrated 
a correlation between expression of EB6 and GL183 and target 
cell protection by HLA-C. From family studies and analysis 
of HLA-C transfectants,  two NK target specificities  (desig- 
nated group 1 and group 2) corresponding to a dimorphic 
sequence motif at amino acids 77 and 80 of HLA-C alleles 
have been defined (14, 22, 24). The NKB1 molecule is dis- 
tinct both in class I HLA specificity and structure from EB6 
and GL183. Certain NKB1 + NK clones have the ability to 
recognize HLA-C alleles  of the group  1 or 2  specificities. 
EB6/GL183 and NKB1 are all structurally different from the 
murine Ly-49 receptors, which are disulfide-linked homodimers 
(9). Furthermore, the 70-kD NKB1 glyeoprotein appears larger 
on SDS-PAGE than the EB6 and GL183 glycoprotdns, which 
migrate at 58 kD. Further understanding of the relationship 
between these various NK receptors will come from com- 
parison of the sequences of the cloned genes.  Nonethdess, 
the results are compatible with the existence of distinct NK 
receptors for HLA-B and HLA-C on a single NK done that 
function independently. 
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